Market Research Logo

Neuroblastoma - Pipeline Review, H1 2018

Neuroblastoma - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Neuroblastoma - Overview
Neuroblastoma - Therapeutics Development
Neuroblastoma - Therapeutics Assessment
Neuroblastoma - Companies Involved in Therapeutics Development
Neuroblastoma - Drug Profiles
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Neuroblastoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2018
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Alissa Pharma, H1 2018
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2018
Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2018
Neuroblastoma - Pipeline by Autolus Ltd, H1 2018
Neuroblastoma - Pipeline by Bayer AG, H1 2018
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2018
Neuroblastoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2018
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2018
Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2018
Neuroblastoma - Pipeline by Cebiotex SL, H1 2018
Neuroblastoma - Pipeline by Celgene Corp, H1 2018
Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Cellectar Biosciences Inc, H1 2018
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2018
Neuroblastoma - Pipeline by CorMedix Inc, H1 2018
Neuroblastoma - Pipeline by Curis Inc, H1 2018
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2018
Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2018
Neuroblastoma - Pipeline by Epizyme Inc, H1 2018
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2018
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Neuroblastoma - Pipeline by GC Pharma, H1 2018
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2018
Neuroblastoma - Pipeline by ID Pharma Co Ltd, H1 2018
Neuroblastoma - Pipeline by Ignyta Inc, H1 2018
Neuroblastoma - Pipeline by Ipsen SA, H1 2018
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Kazia Therapeutics Ltd, H1 2018
Neuroblastoma - Pipeline by Loxo Oncology Inc, H1 2018
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018
Neuroblastoma - Pipeline by MacroGenics Inc, H1 2018
Neuroblastoma - Pipeline by MediaPharma SRL, H1 2018
Neuroblastoma - Pipeline by Merck & Co Inc, H1 2018
Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2018
Neuroblastoma - Pipeline by Novartis AG, H1 2018
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2018
Neuroblastoma - Pipeline by Pfizer Inc, H1 2018
Neuroblastoma - Pipeline by Phylogica Ltd, H1 2018
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by Recombio SL, H1 2018
Neuroblastoma - Pipeline by Ribomic Inc, H1 2018
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2018
Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2018
Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H1 2018
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2018
Neuroblastoma - Pipeline by TheraBiologics Inc, H1 2018
Neuroblastoma - Pipeline by Trellis Bioscience Inc, H1 2018
Neuroblastoma - Pipeline by ZIOPHARM Oncology Inc, H1 2018
Neuroblastoma - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Neuroblastoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report